These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 8466541

  • 1. Fluvoxamine is a potent inhibitor of cytochrome P4501A2.
    Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S.
    Biochem Pharmacol; 1993 Mar 24; 45(6):1211-4. PubMed ID: 8466541
    [Abstract] [Full Text] [Related]

  • 2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun 24; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 3. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine.
    Rasmussen BB, Maënpää J, Pelkonen O, Loft S, Poulsen HE, Lykkesfeldt J, Brøsen K.
    Br J Clin Pharmacol; 1995 Feb 24; 39(2):151-9. PubMed ID: 7742153
    [Abstract] [Full Text] [Related]

  • 4. Inhibitors of imipramine metabolism by human liver microsomes.
    Skjelbo E, Brøsen K.
    Br J Clin Pharmacol; 1992 Sep 24; 34(3):256-61. PubMed ID: 1389950
    [Abstract] [Full Text] [Related]

  • 5. Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2.
    Jensen KG, Poulsen HE, Doehmer J, Loft S.
    Pharmacol Toxicol; 1995 Apr 24; 76(4):286-8. PubMed ID: 7617560
    [Abstract] [Full Text] [Related]

  • 6. Involvement of CYP2E1 as A low-affinity enzyme in phenacetin O-deethylation in human liver microsomes.
    Kobayashi K, Nakajima M, Oshima K, Shimada N, Yokoi T, Chiba K.
    Drug Metab Dispos; 1999 Aug 24; 27(8):860-5. PubMed ID: 10421611
    [Abstract] [Full Text] [Related]

  • 7. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine.
    von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI.
    Psychopharmacology (Berl); 1996 Dec 24; 128(4):398-407. PubMed ID: 8986010
    [Abstract] [Full Text] [Related]

  • 8. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.
    Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE.
    Br J Clin Pharmacol; 1992 Sep 24; 34(3):262-5. PubMed ID: 1389951
    [Abstract] [Full Text] [Related]

  • 9. The pharmacogenetics of the selective serotonin reuptake inhibitors.
    Brøsen K.
    Clin Investig; 1993 Dec 24; 71(12):1002-9. PubMed ID: 8124052
    [Abstract] [Full Text] [Related]

  • 10. Are pharmacokinetic drug interactions with the SSRIs an issue?
    Brøsen K.
    Int Clin Psychopharmacol; 1996 Mar 24; 11 Suppl 1():23-7. PubMed ID: 8732441
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes.
    Hemeryck A, De Vriendt C, Belpaire FM.
    Eur J Clin Pharmacol; 1999 Feb 24; 54(12):947-51. PubMed ID: 10192756
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI.
    J Clin Psychopharmacol; 1995 Apr 24; 15(2):125-31. PubMed ID: 7782485
    [Abstract] [Full Text] [Related]

  • 13. CYP2C9 is a principal low-affinity phenacetin O-deethylase: fluvoxamine is not a specific CYP1A2 inhibitor.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
    Drug Metab Dispos; 1999 Dec 24; 27(12):1519-22. PubMed ID: 10627170
    [No Abstract] [Full Text] [Related]

  • 14. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.
    Härtter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C.
    J Clin Psychopharmacol; 2001 Apr 24; 21(2):167-74. PubMed ID: 11270913
    [Abstract] [Full Text] [Related]

  • 15. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brøsen K.
    Eur J Clin Pharmacol; 1996 Apr 24; 51(1):73-8. PubMed ID: 8880055
    [Abstract] [Full Text] [Related]

  • 16. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors.
    Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brøsen K.
    Eur J Clin Pharmacol; 1998 May 24; 54(3):261-4. PubMed ID: 9681670
    [Abstract] [Full Text] [Related]

  • 17. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
    Danie WA, Syrek M, Ryłko Z, Wójcikowski J.
    Pol J Pharmacol; 2001 May 24; 53(4):351-7. PubMed ID: 11990081
    [Abstract] [Full Text] [Related]

  • 18. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.
    Brøsen K.
    Clin Pharmacokinet; 1995 May 24; 29 Suppl 1():20-5. PubMed ID: 8846619
    [Abstract] [Full Text] [Related]

  • 19. Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.
    Sy SK, Tang BK, Pastrakuljic A, Roberts EA, Kalow W.
    Eur J Clin Pharmacol; 2001 Aug 24; 57(5):377-86. PubMed ID: 11599655
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2.
    Kobayashi K, Nakajima M, Chiba K, Yamamoto T, Tani M, Ishizaki T, Kuroiwa Y.
    Br J Clin Pharmacol; 1998 Apr 24; 45(4):361-8. PubMed ID: 9578183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.